Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J. · 2014
Read Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. by Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4167545.txt.
Introduction
Corine M. Beaufort, James D. Brenton, and ten co-authors profiled a panel of ovarian cancer cell lines in PLoS ONE in 2014. Ovarian cancer comes in many forms, and drug tests in the lab only mean something if the cell lines used match real tumour types. About 100 lines exist in public collections, yet most had never been described in a uniform way.
The team grew 39 lines under the same conditions and measured growth, gene activity, DNA changes, and drug response. Fourteen lines fit high-grade serous cancer, the most common deadly form. The lines also fell into three shape groups, named Epithelial, Round, and Spindle, and the Spindle group showed more genes tied to cell movement. The panel helps labs pick lines that fit the cancer they study.
Catalog record
| CREATOR | Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes By Corine M Beaufort, Jean C A Helmijr, Anna M Piskorz, Marlous Hoogstraat, Kirsten Ruigrok-Ritstier, Nicolle Besselink, Muhammed Murtaza, Wilfred F J van IJcken, Anouk A J Heine, Marcel Smid, Marco J Koudijs, James D Brenton Published in: PLoS ONE DOI: 10.1371/journal.pone.0103988 ABSTRACT Abstract Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer. INTRODUCTION Epithelial ovarian cancer is the most lethal gynaecological malignancy in the Western world and advanced disease remains incurable for the majority of patients. Despite testing of diverse treatment strategies and new cytotoxic agents, optimal primary therapy and survival rates have not substantially changed since the introduction of platinum and taxane treatment [1]–[3]. Recent insights have indicated that ovarian cancer is a collective term for invasive pelvic cancers that are derived from different tissues with distinct histological and epidemiological features. The five major histiotypes have been shown to have specific genetic profiles and should be treated as distinct diseases. High-grade serous (HGS) carcinoma represents 80% of ovarian cancers and is defined by TP53 mutation (96%), homologous recombination DNA repair defects (∼50%), CCNE1 amplification and genomic instability [4]–[6]. By contrast, low-grade serous carcinomas are TP53 wildtype and show frequently activating RAS pathway mutations [7], [8]. The remaining histiotypes are mucinous, endometrioid and clear cell [3]. Activating RAS pathway mutations are found in ∼40% of the mucinous tumours while endometrioid and clear cell tumours have PIK3CA (PI3Kinase component, 12%, 31% respectively), and ARID1A mutations (30%, 46%, respectively) [4], [5], [9], [10]. Furthermore, large studies have identified several molecular subtypes of HGS based on gene and microRNA expression [4], [11]. These subtypes suggest associations with specific biological processes (such as reactive stroma, mesenchymal, immunoreactive and proliferation) and poor prognosis, for example in the C1 stromal-subtype identified by Tothill et al. [4], [11]. Further exploring the clinical characteristics of these biological different subtypes and identifying an optimal treatment could identify new therapeutic strategies. It is imperative that experimentally tractable in vitro models, such as cell lines, accurately represent the different histological and molecular subtypes in order to test new subtype-specific treatment strategies. Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12]–[17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology. Since 1990, an average of approximately 100 papers/year are published that rely upon ovarian cancer cell lines as a model. A major limitation for these studies is the fact that for most of ovarian cell lines their origin is poorly defined and owing to inadequate characterization it is not known which distinct histological or molecular subtype is represented. We here describe an extensive and uniform characterization of a collection of 39 ovarian cancer cell lines commonly used for in vitro studies. We identified histological as well as morphological subtypes which associate with clinical pathological characteristics of ovarian carcinomas as well as prognosis. Furthermore, the morphological subtypes associate with the molecular subtypes identified by Tothill et al. [11]. In summary, these results can serve as a guide to select appropriate cell lines representing different histological and molecular subtype of ovarian cancer for in vitro therapeutic studies. MATERIALS AND METHODS Cell lines and culturing Cell lines studied were CAOV3, CAOV4, ES-2, OV-90, OVCAR3, TOV-112D, TOV-21G, UWB1.289, UWB1.289+BRCA1 (purchased from ATCC), 59M, A2780, A2780CIS, A2780ADR, ‘COLO720E’, COV318, COV362, COV362.4, COV413A, COV413B, COV504, COV644, OAW28, OAW42, OV56, OV7, OV17R, PEA1, PEA2, PEO1, PEO4, PEO14, PEO16, PEO23, SKOV3 (purchased from the European collection of cell cultures, ECACC via Sigma), 2774, A2780, HOC7, SKOV3, SKOV6 (courtesy of Gunter Daxenbichler, Dept. of Obstetrics and Gynaecology, University of Innsbruck, Austria), IGROV1 (courtesy of Dr. Irene Hamelers, Institute of Biomembranes, Utrecht University, The Netherlands). Table S1 summarizes the original source of the cell lines. The cell lines A2780 and SKOV3 were both obtained from an academic laboratory and also purchased from ECACC, and are described here as ‘A2780 ECACC’ and ‘SKOV3 ECACC’. Thirty-nine of the 40 cell lines were grown as monolayers, except for the semi-adherent cell line ‘COLO720E’ for which floating and attached cells were passaged. Attached cells were fully disaggregated by trypsinization between passages. The cell lines were maintained at 37°C in an incubator with humidified air with 5% CO2. All cell lines were initially cultured using the medium and supplements as recommended by the suppliers. In contrast to other studies, we cultured all cell lines under the same culture conditions to avoid biases due to varying concentrations of supplements within different media (e.g. growth factors) or different percentages of serum. All cell lines were cultured in RPMI-1640 glutamax, Gibco/Invitrogen supplemented with 10% FCS (Lonza, source: Brazilian, Lot nr 1SB002), 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml gentamycin. All experiments and nucleic acid isolations were performed after culturing the cell lines for at least one month using these standard conditions. UWB1.289 is a BRCA1-null cell line from woman with a germline BRCA1 2594delC mutation. UWB1.289+BRCA1 is stable transfected with a pcDNA3 plasmid containing a BRCA1 insert and was maintained with 200 µg/ml Geneticin (G418) to maintain selection for transfected cells. A2780ADR and A2780CIS were challenged once a month with 100 nM Doxorubicin and 1 µM Cisplatin respectively. Short tandem repeat analysis The PowerPlex 16 System (Promega) was used according to the manufacturer's protocol using an ABI PRISM 3100 to generate an STR (Short tandem repeat) fingerprint of each cell line to determine unique identity and/or lack of co-culture contamination. In addition, the STR profile was checked before and during culturing of the cells to ensure that cross-contamination or erroneous substitution did not occur. Growth curves and drug sensitivity